Amplatzer Paraclose PVL Occluder
ABBOTT MEDICAL · Decision date Oct 27, 2026
What did the FDA approve?
FDA records P260019 as an original PMA application. The recorded decision is approval, dated Oct 27, 2026.
FDA approval order statement
The Amplatzer Paraclose PVL Occluder is indicated for use in patients who have developed a clinically significant paravalvular leak associated with a surgical aortic or mitral valve prosthesis.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2026
Regulatory record facts
- Identifier
- P260019
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- SJT
- Decision code
- APPR
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Para-device leak occluder.
- Applicant
- Abbott Medical
- Product code
- SJT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P260019 received
Application receipt date recorded by FDA.
P260019 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P260019. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P260019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records